GLP-1 receptor agonists market to reach $125 billion by 2033


Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData.

GLP-1 receptor agonists like Ozempic (semaglutide) are a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity.

GlobalData’s report predicts that GLP-1 receptor agonists will dominate the metabolic diseases space in the next 10 years.

Key opinion leaders interviewed by GlobalData said that patients usually ask their doctors for these specific medicines.

Costanza Alciati, Pharma Analyst at GlobalData, commented: “There are currently 10 GLP-1 receptor agonists approved for type 2 diabetes and three for obesity, but many more are expected to reach the market in the next five to 10 years. Indeed, there are 51 products in clinical development for obesity and/or type 2 diabetes, which exploit the GLP-1 receptor agonist mechanism, often coupled with other actions.”

According to GlobalData, more than 190 million people currently live with type 2 diabetes and/or obesity in 7MM, and the numbers will be growing at an annual growth rate (AGR) of 1.35% and 0.57% for type 2 diabetes and obesity, respectively, in the next 10 years.

Alciati continued: “At present, Ozempic (Wegovy for obesity) and Mounjaro dominate the GLP-1 receptor agonist space. But there is an opportunity for new players to join the race, as the market is vast. Some of the therapies in Phase III are very promising and GlobalData expects them to reach the billion-dollar sales mark within a couple of years from their launch.”

It was recently revealed that in a Phase III trial, Ozempic reduced the risk of adverse cardiovascular events in patients by 20%.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free